Black-box warning imposed on Seattle Genetics' new lymphoma drug
This article was originally published in Scrip
Executive Summary
A black-box warning about the increased risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, which can result in death, has been added to the labelling of Seattle Genetics' recently approved lymphoma drug Adcetris (brentuximab vedotin), an antibody-drug conjugate directed to CD30.